NGEN-143 / NEUVOGEN - LARVOL DELTA

NEUVOGEN Announces Poster Presentation at the American Association of Cancer Research Annual Meeting (PRNewswire) - "Key Findings: In a fully human in vitro system, NGEN-143 expands effector T cells against a broad repertoire of both tumor-associated antigens and common shared neo-antigens across a wide range of HLA types....NGEN-143 activated T cells efficiently kill human tumor cells in a caspase-3 dependent manner. In the 'immune warm' CT26 mouse tumor model, vaccine abrogates or slows tumor growth – durable protection against rechallenge supports efficient induction of immune memory; vaccine + αPD1 improved survival over αPD1 monotherapy. In the 'immune cold' B16F10 mouse tumor model, our vaccine approach inhibits tumor growth and prolongs survival; vaccine + αPD1 improved survival."

Preclinical • Oncology